0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Effectiveness of Immunosuppressive Therapy in Older Patients with Aplastic Anemia

André Tichelli, MD; Gérard Socié, MD; Michel Henry-Amar, MD; Judith Marsh, MD; Jakob Passweg, MD; Hubert Schrezenmeier, MD; Shaun McCann, MD; Jill Hows, MD; Per Ljungman, MD; Pedro Marin, MD; Aruna Raghavachar, MD; Anna Locasciulli, MD; Alois Gratwohl, MD; Andrea Bacigalupo, MD, for the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party
[+] Article and Author Information

From Kantonsspital Basel, Basel, Switzerland; Hôpital St. Louis, Paris, France; Centre François Baclesse, Caen, France; St. George's Hospital, London, United Kingdom; Universität Ulm, Ulm, Germany; St. James Hospital Trinity College, Dublin, Ireland; Southmead Health Services, Bristol, United Kingdom; Huddinge Hospital, Huddinge, Sweden; Postgraduate School of Haematology, Farreras Valenti, Barcelona, Spain; Ospedale San Gerardo, Monza, Italy; and Ospedale San Martino, Genova, Italy.


Ann Intern Med. 1999;130(3):193-201. doi:10.7326/0003-4819-130-3-199902020-00004
Text Size: A A A

Background: Immunosuppressive therapy has been used for successful treatment of severe aplastic anemia, but little information is available on outcome in older patients.

Objective: To evaluate outcome in patients older than 50 years of age who received immunosuppressive therapy for aplastic anemia.

Design: Retrospective cohort study.

Setting: 56 centers of the European Group for Blood and Marrow Transplantation (EBMT).

Patients: 810 patients with aplastic anemia reported between 1974 and 1997. Patients were evaluated according to age group: 60 years of age or older (n = 127), 50 to 59 years of age (n = 115), and 20 to 49 years of age (n = 568; reference group).

Intervention: Antilymphocyte globulin, cyclosporine, or both.

Measurements: Survival, cause of death, response to treatment, relapse rate, and risk for late complications were analyzed in all patients and by age group.

Results: The 5-year survival rate was 57% (95% CI, 46% to 66%) in patients 50 to 59 years of age and 50% (CI, 39% to 60%) in patients 60 years of age or older compared with 72% (CI, 68% to 76%) in patients younger than 50 years of age (P < 0.001). Response to therapy, relapse rate, and risk for clonal complications were similar in all three age groups (P > 0.2). Age was significantly associated with an increased risk for death (relative risk compared with patients 20 to 49 years of age, 1.80 [CI, 1.29 to 2.52] for patients 50 to 59 years of age and 2.57 [CI, 1.87 to 3.53] for patients ≥ 60 years of age), mainly because of bleeding or infection (P = 0.02). Response to immunosuppressive therapy in all patients at 12 months was 62% (CI, 58% to 66%); no difference was seen among the age groups in multivariate analysis (P > 0.2). Sixty-six of the 379 responding patients (17%) subsequently had relapse. The risk for clonal disorders at 10 years was 20% (CI, 15% to 27%).

Conclusions: Response to immunosuppression in aplastic anemia is independent of age, but treatment is associated with increased mortality in older patients.

Figures

Grahic Jump Location
Figure.
Five-year survival curves by age groups (115 patients 50 to 59 years of age [solid line], 127 patients ≥ 60 years of age [dotted line], and 568 reference patients 20 to 49 years of age [dashed line]), adjusted for neutrophil count and year of treatment.
Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)